Shore Capital Reiterates “Buy” Rating for ECO Animal Health Group (LON:EAH)

ECO Animal Health Group (LON:EAH)‘s stock had its “buy” rating reissued by Shore Capital in a research report issued to clients and investors on Friday,Digital Look reports.

ECO Animal Health Group Trading Up 4.6 %

LON EAH opened at GBX 74.80 ($0.95) on Friday. The company has a market cap of £50.67 million, a price-to-earnings ratio of 3,740.00 and a beta of -0.05. ECO Animal Health Group has a twelve month low of GBX 60 ($0.76) and a twelve month high of GBX 135 ($1.71). The company has a quick ratio of 2.14, a current ratio of 2.96 and a debt-to-equity ratio of 4.31. The business’s fifty day moving average is GBX 75.40 and its 200 day moving average is GBX 102.21.

About ECO Animal Health Group

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, mange, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle.